2型糖尿病患者泛血管疾病风险评估与管理中国专家共识(2022版)

Chinese expert consensus on the risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus(2022 edition)

泛血管疾病不仅是2型糖尿病(T2DM)常见的合并疾病, 也是T2DM患者致残和致死的首要原因。为促进多学科合作和跨学科整合, 早期发现T2DM患者的泛血管疾病, 由中国医师协会心血管内科医师分会牵头组织心血管病学、内分泌学、肾脏病学、神经病学以及健康管理等领域的中国学者组成了《2型糖尿病患者泛血管疾病风险评估与管理中国专家共识(2022版》专家组, 对国内外相关学科最新循证医学证据和重要进展进行梳理, 制定了本共识。共识涵盖了T2DM患者泛血管疾病的流行病学特征、病理生理机制、多学科协作诊疗、风险评估以及管理等内容, 突出了T2DM患者泛血管疾病早期风险评估的内容, 即每年至少进行1次危险因素、血管结构和功能以及靶器官损伤的评估, 强调T2DM患者泛血管疾病的管理需要由患者和多学科医师共同参与, 在生活方式干预的基础上强化血糖、血压、血脂的控制和抗血小板治疗。本共识将有助于指导和帮助临床医师对T2DM患者泛血管疾病进行规范化综合管理, 并改善患者预后。

Panvascular disease is not only a common comorbidity of type 2 diabetes mellitus(T2DM),but also the leading cause of disability and death in patients with T2DM.To promote multidisciplinary cooperation,interdisciplinary integration,and early detection of panvascular diseases in T2DM patients,a panel composed of Chinese experts in cardiovascular disease,endocrinology,nephrology,neurology,and health management led by Chinese College of Cardiovascular Physicians was established and developed this consensus based on the latest evidence-based medical research and crucial progress in the related disciplines.This consensus covers the epidemiological characteristics,pathophysiological mechanisms,multidisciplinary collaborative diagnosis and treatment,as well as risk assessment and management,and highlights the early risk assessment of panvascular disease in patients with T2DM(assess risk factors,vascular structure and function,and target organ damage at least annually).This consensus also emphasizes that managing panvascular disease in patients with T2DM requires the participation of both patients and multidisciplinary physicians and the necessity of strengthening the control of blood glucose,blood pressure,blood lipids,and antiplatelet therapy based on lifestyle interventions.The consensus will standardize the comprehensive clinical management of panvascular disease in patients with T2DM and improve patient prognosis.